(Q38047846)

27 August 2017

title

Biomarkers of therapeutic response to BCL2 antagonists in cancer (English)

1 reference

27 August 2017

0 references

Lloyd T Lam

1

1 reference

27 August 2017

Haichao Zhang

series ordinal

2

1 reference

27 August 2017

Brenda Chyla

series ordinal

3

1 reference

27 August 2017

publication date

1 December 2012

1 reference

Molecular Diagnosis and Therapy

27 August 2017

published in

1 reference

27 August 2017

volume

16

1 reference

27 August 2017

issue

6

1 reference

27 August 2017

page(s)

347-356

1 reference

Hallmarks of Cancer: The Next Generation

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Promoting apoptosis as a strategy for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

BCL2 family in DNA damage and cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

G0 function of BCL2 and BCL-xL requires BAX, BAK, and p27 phosphorylation by Mirk, revealing a novel role of BAX and BAK in quiescence regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

The BCL-2 protein family: opposing activities that mediate cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Perturbation of the Bcl-2 network and an induced Noxa/Bcl-xL interaction trigger mitochondrial dysfunction after DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

ER stress triggers apoptosis by activating BH3-only protein Bim

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Endoplasmic reticulum stress-induced apoptosis: multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

21 January 2018

The BCL-2 family reunion

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Still embedded together binding to membranes regulates Bcl-2 protein interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Bcl-2-family proteins and hematologic malignancies: history and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Bcl-2 family proteins: regulators of chemoresistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Mcl-1 is a potential therapeutic target in multiple types of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Myeloid cell factor-1 is a critical survival factor for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

The landscape of somatic copy-number alteration across human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

BCL-2 family antagonists for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Different forms of cell death induced by putative BCL2 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Investigations on gossypol: past and present developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

RETRACTED: Inactivation of MAP kinase signalling in Myc transformed cells and rescue by LiCl inhibition of GSK3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Structural biology of the Bcl-2 family of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

ABT-737 is highly effective against molecular subgroups of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Programmed anuclear cell death delimits platelet life span.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Utilizing circulating tumor cells: challenges and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Detection, clinical relevance and specific biological properties of disseminating tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Evaluation of the branched-chain DNA assay for measurement of RNA in formalin-fixed tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

The molecular classification of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Global gene disruption in human cells to assign genes to phenotypes by deep sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

miR-15 and miR-16 induce apoptosis by targeting BCL2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0003-6

The domains of apoptosis: a genomics perspective

21 January 2018

1 reference

12 December 2020

Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma

1 reference

12 December 2020

BCL-X expression in multiple myeloma: possible indicator of chemoresistance

1 reference

12 December 2020

Bcl-2 family proteins are essential for platelet survival.

1 reference

12 December 2020

The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile

1 reference

12 December 2020

Expression of bcl-xL can confer a multidrug resistance phenotype

1 reference

12 December 2020

Involvement of the bcl-2 gene in human follicular lymphoma

1 reference

12 December 2020

Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies.

1 reference

12 December 2020

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

1 reference

12 December 2020

Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer

1 reference

12 December 2020

10.1007/S40291-012-0003-6

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1008529944

0 references

1 reference